Osteoblastic mTORC1 accelerates acute myeloid leukemia growth via IL-6 signaling

Fukasawa Kazuya, Yamada Takanori, Horie Tetsuhiro, Hiraiwa Manami, Kaneda Katsuyuki, Hirao Atsushi, Hinoi Eiichi

doi:10.1254/jpssuppl.93.0_1-ss-53

Bibliographic Information

Other Title

骨芽細胞のmTORC1はIL-6シグナルを介して急性骨髄性白血病の進展を促進する

Abstract

<p>Although there is increasing evidence that bone forming osteoblasts provide a microenvironment for leukemic stem cells (LSCs) and play a critical role in the maintenance and retention of LSCs, how those cells contribute to leukemia growth remains largely unclear. The mTOR complex 1 (mTORC1), a member of the serine/threonine kinases, is known to regulate the cellular function in various cell types. Using an MLL-AF9 acute myeloid leukemia (AML) mouse model, we found that AML cells enhance the mTORC1 activity in osteoblasts in vivo and in vitro. The osteoblast specific inactivation of Tsc1, a negative regulator of mTORC1, drives differentiation of hematopoietic stem cells (HSCs) toward myeloid lineage during steady state and promotes AML growth. Among the secretory factors examined, interleukine-6 (IL-6) was the most upregulated gene in Tsc1-deficient osteoblasts. Genetic inhibition of IL-6 receptor in AML cells significantly rescued tumor growth in osteoblast specific Tsc1-deficient mice. Collectively, our studies suggest mTORC1/IL-6 axis in osteoblastic niche could be a novel therapeutic target for AML.</p>

Journal

Proceedings for Annual Meeting of The Japanese Pharmacological Society

Proceedings for Annual Meeting of The Japanese Pharmacological Society 93 (0), 1-SS-53-, 2020

Japanese Pharmacological Society

Keywords

Details 詳細情報について

CRID: 1390283659860034048

NII Article ID: 130007811370

DOI: 10.1254/jpssuppl.93.0_1-ss-53

ISSN: 24354953

Web Site: https://www.jstage.jst.go.jp/article/jpssuppl/93/0/93_1-SS-53/_pdf

Text Lang: ja

Data Source

JaLC
Crossref
CiNii Articles

Abstract License Flag: Disallowed

Export